Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 60.37B | 63.51B | 54.47B | 52.03B | 51.61B | 52.32B |
Gross Profit | 8.20B | 8.96B | 8.45B | 8.13B | 8.12B | 8.07B |
EBITDA | 878.50M | 1.68B | 1.38B | 2.33B | 2.69B | 2.62B |
Net Income | -800.00M | -367.00M | -351.00M | 333.00M | 447.00M | 426.00M |
Balance Sheet | ||||||
Total Assets | 31.10B | 31.92B | 29.49B | 23.42B | 23.75B | 24.72B |
Cash, Cash Equivalents and Short-Term Investments | 2.24B | 4.92B | 7.15B | 4.74B | 3.99B | 4.60B |
Total Debt | 14.25B | 14.28B | 12.75B | 9.14B | 9.91B | 10.70B |
Total Liabilities | 24.10B | 25.01B | 22.05B | 16.43B | 17.05B | 18.39B |
Stockholders Equity | 6.95B | 6.87B | 7.36B | 6.88B | 6.61B | 6.22B |
Cash Flow | ||||||
Free Cash Flow | 349.50M | 609.00M | 2.10B | 1.98B | 247.00M | 1.39B |
Operating Cash Flow | 427.00M | 1.31B | 2.71B | 2.52B | 713.00M | 1.95B |
Investing Cash Flow | -1.29B | -4.46B | -3.12B | -703.00M | -292.00M | -1.08B |
Financing Cash Flow | 1.95B | 939.00M | 2.77B | -1.07B | -1.03B | -728.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | ¥19.24B | 6.66 | 8.52% | 1.86% | 3.70% | 37.00% | |
67 Neutral | ¥11.14B | 15.29 | 7.83% | 1.25% | 4.08% | 51.63% | |
66 Neutral | ¥43.69B | 10.11 | 11.53% | 1.27% | 6.65% | 12.77% | |
63 Neutral | ¥14.09B | 11.59 | 7.77% | 2.59% | 5.93% | -36.11% | |
60 Neutral | ¥20.53B | -10.54 | -10.03% | 3.54% | 12.75% | -191.21% | |
58 Neutral | ¥6.15B | ― | ― | 2.67% | 15.66% | 56.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Pharmarise Holdings Corporation reported a significant increase in net sales for the first nine months of the fiscal year ending May 31, 2025, with a 14.5% year-on-year growth. However, the company faced challenges with a substantial decline in operating profit and a net loss attributable to the owners, indicating potential operational difficulties. The financial results reflect a complex market environment, and the company has made changes in accounting policies and added a new company to its consolidation scope, which may impact future performance.